Microbot Medical Inc. MBOT recently announced that Baptist Hospital of Miami, which includes Miami Cardiac & Vascular Institute and Miami Cancer Institute, has completed its first clinical procedure in a patient utilizing the LIBERTY Endovascular Robotic Surgical System. Baptist Hospital of Miami is the second site to perform clinical procedures as part of MBOT’s pivotal human clinical trial. The first clinical case was performed at Boston, MA-based Brigham and Women’s Hospital. The latest announcement is a significant step for Microbot Medical toward its future submission to the FDA for the commercialization of the LIBERTY Endovascular Robotic Surgical System. It will become the first system to provide remote operation following a potential approval that will likely drive penetration for endovascular interventional procedures. Significance of the Announcement The clinical case at the Baptist Hospital of Miami was performed shortly after the announcement regarding its participation as a clinical trial site early this month. The trial is part of the Investigational Device Exemption (IDE) for LIBERTY. Per Microbot Medical’s management, the progress of the clinical study, with two sites actively enrolling patients within a couple of weeks, is encouraging. The company expects its results to support the future submission to the FDA and subsequent commercialization of the LIBERTY system. Industry Prospects Per a report by Future Market Insights, the global robotic-assisted endovascular systems industry is expected to reach $214.7 million by 2033 from $94 million in 2023 at a CAGR of 8.6%. Factors like the increasing adoption of advanced robotic-assisted endovascular systems and the growing demand for innovative, minimally-invasive surgical procedures are likely to drive the market. Given the market potential, the latest progress with its pivotal human clinical trial is expected to provide a significant boost to Microbot Medical’s business in the niche space. Notable Developments Last month, Microbot Medical received the FDA’s approval to proceed with its pivotal human clinical trial as part of its IDE application for its LIBERTY Endovascular Robotic Surgical System. In April, Microbot Medical reported that the first phase of the previously announced collaboration with Corewell Health has been completed. The collaboration demonstrated the LIBERTY System's technical capabilities and outlined potential future applications in a range of endovascular interventions. Microbot Medical, in February, announced that it has filed an IDE application with the FDA. The IDE application follows the completion of multiple preclinical activities performed to provide preliminary safety and effectiveness information, and its approval by the FDA would allow the company to commence its pivotal human clinical trial in the United States. Price Performance Microbot Medical stock has lost 61.1% compared with the 1.1% decline of the industry. The S&P 500 has witnessed 27.4% growth in the said time frame. Zacks Investment Research Image Source: Zacks Investment Research Zacks Rank & Stocks to Consider Currently, Microbot Medical carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader medical space are DaVita Inc. DVA, Stryker Corporation SYK and Elevance Health, Inc. ELV. DaVita, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 13.6%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 29.4%. You can see the complete list of today’s Zacks #1 Rank stocks here. DaVita’s shares have gained 33.7% compared with the industry’s 10.3% rise in the past year. Stryker, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 10.6%. SYK’s earnings surpassed estimates in each of the trailing four quarters, with the average being 4.9%. Stryker has gained 13.2% against the industry’s 2.3% decline in the past year. Elevance Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.2%. ELV’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 2.8%. Elevance Health’s shares have rallied 29.1% compared with the industry’s 5.9% rise in the past year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Stryker Corporation (SYK):Free Stock Analysis Report DaVita Inc. (DVA):Free Stock Analysis Report Microbot Medical Inc. (MBOT):Free Stock Analysis Report Elevance Health, Inc. (ELV):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Microbot Medical (MBOT) Progresses in Its Human Clinical Trial
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...